Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$24.75 - $40.66 $476,091 - $782,135
-19,236 Reduced 62.11%
11,737 $290,000
Q4 2023

Feb 07, 2024

BUY
$32.31 - $52.32 $174,183 - $282,057
5,391 Added 21.07%
30,973 $1.13 Million
Q3 2023

Nov 02, 2023

SELL
$47.3 - $70.6 $2.31 Million - $3.44 Million
-48,741 Reduced 65.58%
25,582 $1.23 Million
Q2 2023

Aug 07, 2023

BUY
$48.26 - $78.59 $938,850 - $1.53 Million
19,454 Added 35.46%
74,323 $5.07 Million
Q1 2023

May 09, 2023

SELL
$46.97 - $58.27 $53,451 - $66,311
-1,138 Reduced 2.03%
54,869 $2.66 Million
Q4 2022

Feb 09, 2023

BUY
$52.05 - $65.0 $1.93 Million - $2.4 Million
36,992 Added 194.54%
56,007 $3.37 Million
Q3 2022

Nov 09, 2022

SELL
$25.16 - $60.63 $375,412 - $904,660
-14,921 Reduced 43.97%
19,015 $1.15 Million
Q2 2022

Aug 10, 2022

BUY
$22.73 - $39.98 $76,440 - $134,452
3,363 Added 11.0%
33,936 $921,000
Q1 2022

May 09, 2022

SELL
$30.27 - $49.22 $301,247 - $489,837
-9,952 Reduced 24.56%
30,573 $1.12 Million
Q4 2021

Feb 09, 2022

BUY
$42.11 - $73.26 $376,884 - $655,677
8,950 Added 28.35%
40,525 $2 Million
Q3 2021

Nov 09, 2021

BUY
$48.2 - $78.89 $2,217 - $3,628
46 Added 0.15%
31,575 $2.25 Million
Q2 2021

Aug 10, 2021

BUY
$21.63 - $57.65 $96,988 - $258,502
4,484 Added 16.58%
31,529 $1.62 Million
Q1 2021

May 10, 2021

BUY
$11.0 - $28.24 $22,737 - $58,372
2,067 Added 8.28%
27,045 $679,000
Q4 2020

Feb 08, 2021

BUY
$10.12 - $13.94 $64,100 - $88,295
6,334 Added 33.97%
24,978 $300,000
Q3 2020

Nov 06, 2020

BUY
$9.93 - $13.47 $116,826 - $158,474
11,765 Added 171.03%
18,644 $186,000
Q1 2018

May 14, 2018

SELL
$27.95 - $45.04 $144,808 - $233,352
-5,181 Reduced 42.96%
6,879 $253,000
Q4 2017

Feb 13, 2018

BUY
$35.44 - $63.76 $223,484 - $402,070
6,306 Added 109.59%
12,060 $452,000
Q3 2017

Nov 02, 2017

BUY
$53.83 - $67.75 $309,737 - $389,833
5,754
5,754 $373,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $668M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.